当前位置: X-MOL 学术Transpl. Immunol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Pre-transplantation plasma vitamin D levels and acute graft-versus-host disease after myeloablative hematopoietic cell transplantation in adults
Transplant Immunology ( IF 1.5 ) Pub Date : 2021-07-15 , DOI: 10.1016/j.trim.2021.101437
Lars Klingen Gjærde 1 , Sisse Rye Ostrowski 2 , Niels Smedegaard Andersen 3 , Lone Smidstrup Friis 3 , Brian Kornblit 3 , Søren Lykke Petersen 3 , Ida Schjødt 3 , Henrik Sengeløv 1
Affiliation  

Background

The association between vitamin D and acute graft-versus-host disease (GvHD) remains controversial, especially for patients receiving myeloablative conditioning.

Methods

We measured pre-transplantation plasma vitamin D (25-hydroxyvitamin D3 + D2) levels by competitive electrochemiluminescence in plasma samples from 116 adult patients who underwent a myeloablative allogeneic transplantation at Rigshospitalet, Copenhagen between July 2015 and August 2018.

Results

The median (Q1, Q3) pre-transplantation plasma vitamin D level was 64 (47, 85) nmol/L (normal range: 50–160 nmol/L). Vitamin D insufficiency (<50 nmol/L) and moderate deficiency (<25 nmol/L) were observed in 29% and 8% of patients, respectively. No patients had a severe deficiency (<12 nmol/L). Pre-transplantation vitamin D levels were slightly higher in patients who later developed grade II–IV acute GvHD (mean difference: 8.1 nmol/L), but the 95% confidence interval [CI] encompassed clinically insignificant differences (CI: −2.2, 19.2 nmol/L). From multivariable logistic regression, we found that a patient with a pre-transplantation vitamin D level of 85 nmol/L (Q3) had 1.5 times higher odds of grade II–IV acute GvHD than a patient with a level of 47 nmol/L (Q1; CI of odds ratio: 0.84, 2.7; adjusted for patient age, donor type, use of anti-thymocyte globulin, and use of 12 Gy total-body irradiation). Patients with pre-transplantation vitamin D insufficiency (N = 34) had a cumulative incidence of grade II–IV acute GvHD similar to that of patients with vitamin D sufficiency (26% [CI: 11%, 42%] versus 35% [CI: 25%, 46%], respectively).

Conclusions

Our data did not support an association between pre-transplantation vitamin D levels or vitamin D insufficiency and acute GvHD in adult patients receiving myeloablative conditioning.



中文翻译:

成人清髓性造血细胞移植后的移植前血浆维生素 D 水平和急性移植物抗宿主病

背景

维生素 D 与急性移植物抗宿主病 (GvHD) 之间的关联仍存在争议,尤其是对于接受清髓性预处理的患者。

方法

我们通过竞争性电化学发光测量了 2015 年 7 月至 2018 年 8 月在哥本哈根 Rigshospitalet 接受清髓性异基因移植的 116 名成年患者的血浆样本中的移植前血浆维生素 D(25-羟基维生素 D 3  + D 2 )水平。

结果

移植前血浆维生素 D 水平中位数(Q1、Q3)为 64(47、85)nmol/L(正常范围:50-160nmol/L)。分别有 29% 和 8% 的患者出现维生素 D 不足(<50 nmol/L)和中度缺乏(<25 nmol/L)。没有患者出现严重缺乏(<12 nmol/L)。后来发展为 II-IV 级急性 GvHD 的患者移植前维生素 D 水平略高(平均差异:8.1 nmol/L),但 95% 置信区间 [CI] 包含临床上不显着的差异(CI:-2.2, 19.2毫摩尔/升)。从多变量逻辑回归中,我们发现移植前维生素 D 水平为 85 nmol/L(Q3)的患者发生 II-IV 级急性 GvHD 的几率是 47 nmol/L 患者的 1.5 倍( Q1;优势比 CI:0.84、2.7;根据患者年龄、供体类型、使用抗胸腺细胞球蛋白和使用 12 Gy 全身照射)。移植前维生素 D 不足的患者(N  = 34) 的 II-IV 级急性 GvHD 的累积发生率与维生素 D 充足的患者相似(分别为 26% [CI: 11%, 42%] 和 35% [CI: 25%, 46%] )。

结论

我们的数据不支持接受清髓性预处理的成年患者移植前维生素 D 水平或维生素 D 不足与急性 GvHD 之间的关联。

更新日期:2021-07-18
down
wechat
bug